Differential Effects of Sucrase-Isomaltase Mutants on Its Trafficking and Function in Irritable Bowel Syndrome: Similarities to Congenital Sucrase-Isomaltase Deficiency.
congenital sucrase-isomaltase deficiency
irritable bowel syndrome
protein trafficking
sucrase-isomaltase
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
22 Dec 2020
22 Dec 2020
Historique:
received:
17
11
2020
revised:
14
12
2020
accepted:
18
12
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
4
5
2021
Statut:
epublish
Résumé
Congenital sucrase-isomaltase deficiency (CSID) is a rare metabolic intestinal disorder with reduced or absent activity levels of sucrase-isomaltase (SI). Interestingly, the main symptoms of CSID overlap with those in irritable bowel syndrome (IBS), a common functional gastrointestinal disorder with unknown etiology. Recent advances in genetic screening of IBS patients have revealed rare SI gene variants that are associated with IBS. Here, we investigated the biochemical, cellular and functional phenotypes of several of these variants. The data demonstrate that the SI mutants can be categorized into three groups including immature, mature but slowly transported, and finally mature and properly transported but with reduced enzymatic activity. We also identified SI mutant phenotypes that are deficient but generally not as severe as those characterized in CSID patients. The variable effects on the trafficking and function of the mutations analyzed in this study support the view that both CSID and IBS are heterogeneous disorders, the severity of which is likely related to the biochemical phenotypes of the SI mutants as well as the environment and diet of patients. Our study underlines the necessity to screen for SI mutations in IBS patients and to consider enzyme replacement therapy as an appropriate therapy as in CSID.
Identifiants
pubmed: 33375084
pii: nu13010009
doi: 10.3390/nu13010009
pmc: PMC7822125
pii:
doi:
Substances chimiques
Sucrase-Isomaltase Complex
EC 3.2.1.-
Oligo-1,6-Glucosidase
EC 3.2.1.10
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : NA 331/13-1
Organisme : QOL Medical LLC, Vero Beach, Florida, USA
ID : Non-restricted research grant
Références
J Clin Invest. 1996 Feb 1;97(3):633-41
pubmed: 8609217
J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S13-20
pubmed: 23103643
J Biol Chem. 2012 Sep 14;287(38):31929-38
pubmed: 22851177
J Cell Biol. 1985 Sep;101(3):838-51
pubmed: 3897250
Hum Mutat. 2006 Jan;27(1):119
pubmed: 16329100
J Biol Chem. 2001 Jun 29;276(26):23506-10
pubmed: 11340066
J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S43-5
pubmed: 23103656
JAMA. 2015 Mar 3;313(9):949-58
pubmed: 25734736
J Cell Sci. 1997 Mar;110 ( Pt 5):557-67
pubmed: 9092938
J Biol Chem. 1975 Aug 10;250(15):5735-41
pubmed: 807575
J Biol Chem. 1991 Jul 5;266(19):12313-20
pubmed: 1905719
Gut. 2018 Feb;67(2):263-270
pubmed: 27872184
Clin Gastroenterol Hepatol. 2006 Mar;4(3):276-87
pubmed: 16527688
Biochim Biophys Acta Mol Basis Dis. 2017 Mar;1863(3):817-826
pubmed: 28062276
Gut. 2020 Aug;69(8):1538-1539
pubmed: 31331993
Gut. 2020 Feb;69(2):397-398
pubmed: 30658996
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1673-1676
pubmed: 29408290
J Pediatr Gastroenterol Nutr. 1995 Jul;21(1):1-14
pubmed: 8576798
Gastroenterology. 2009 Mar;136(3):883-92
pubmed: 19121318
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1468-73
pubmed: 24486406